Last reviewed · How we verify
LY3361237 - SC
At a glance
| Generic name | LY3361237 - SC |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus (PHASE2)
- A Study of LY3361237 in Participants With Psoriasis (PHASE1)
- A Study of LY3361237 in Participants With Systemic Lupus Erythematosus (PHASE1)
- A Study of LY3361237 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3361237 - SC CI brief — competitive landscape report
- LY3361237 - SC updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI